Navigation Links
Injection Reverses Heart-Attack Damage
Date:7/23/2009

/p>

When the researchers also stimulated production of a cellular receptor for NRG1, known as ErbB4, cardiomyocyte proliferation was further enhanced, demonstrating that NRG1 works by stimulating this receptor. They also identified the specific kinds of cardiomyocytes (mononucleated) that are most likely to respond to treatment.

In 2007, Kuhn and colleagues first demonstrated that the heart has dormant regenerative capacities that can be reawakened. Kuhn developed a sponge-like patch, soaked in a compound called periostin that is abundant in the developing fetal heart (and in injured skeletal muscle) but scarce in adult hearts. When the patch was placed over the site of cardiac injury in rats, it induced cardiomyocyte proliferation and improved heart function (Nature Medicine 2007; 13:962-9). Similar results were seen in larger animals, and periostin is now in preclinical development at Children's Hospital Boston for future application in human patients with heart failure.

The new work adds a second compound to the heart-regeneration toolbox, and reveals how both periostin and NRG1 work at the cellular and molecular level, an essential step in predicting possible side effects. Both compounds ultimately act on the same cellular pathway, Kuhn found.

"We applied periostin locally at the site of cardiac injury, but NRG1 works when given by systemic injection - a very promising result that suggests it may be feasible to use this in the clinic to treat heart failure," says Kuhn, who won a first prize Young Investigator Award, from the American College of Cardiology in 2007.

The study was funded by the Department of Cardiology at Children's Hospital Boston, the Charles Hood Foundation, and the American Heart Association.

Children's Hospital Boston is home to the world's largest research enterprise
'/>"/>

SOURCE Children's Hospital of Boston
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
3. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
4. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
7. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
8. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
9. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical ... device received 510 (k) OTC clearance by the U.S. ... 100 to be marketed over the Internet for: ... muscle spasms; and minor strains and sprains . ... The AVACEN 100 (MSRP $2495) is a sophisticated medical ...
(Date:10/22/2014)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... focused on the development of oral drug delivery ... its Phase IIa clinical trial of ORMD-0801, the ... 1 diabetes. The trial was conducted in ... Food and Drug Administration (FDA) Investigational New Drug ...
(Date:10/22/2014)... Influenza will affect as many as 200,000 people ... United States as high as 49,000 people.  The ... from person to person in respiratory droplets of coughs and ... death, but kills much fewer people each year than the ... fluids including sweat, saliva, blood and other bodily fluids. The ...
Breaking Medicine Technology:AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2
... 2 Meeting with the FDA for the Fabry Program and Initiation ... ... Quarter, CRANBURY, N.J., Aug. 7 ... pharmacological chaperones for the treatment of human,genetic diseases, today announced financial results ...
... 7 The American Association of Diabetes,Educators ... conducted by Harris,Interactive highlighting communication between people ... healthcare providers. According to the,survey results, 33 ... of,dread relating to insulin injections (eight percent ...
Cached Medicine Technology:Amicus Therapeutics Announces Second Quarter 2008 Financial Results 2Amicus Therapeutics Announces Second Quarter 2008 Financial Results 3Amicus Therapeutics Announces Second Quarter 2008 Financial Results 4Amicus Therapeutics Announces Second Quarter 2008 Financial Results 5Amicus Therapeutics Announces Second Quarter 2008 Financial Results 6Amicus Therapeutics Announces Second Quarter 2008 Financial Results 7Amicus Therapeutics Announces Second Quarter 2008 Financial Results 8Amicus Therapeutics Announces Second Quarter 2008 Financial Results 9Amicus Therapeutics Announces Second Quarter 2008 Financial Results 10Amicus Therapeutics Announces Second Quarter 2008 Financial Results 11Amicus Therapeutics Announces Second Quarter 2008 Financial Results 12New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers 2New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers 3New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers 4
(Date:10/22/2014)... 22, 2014 Akeso Biomedical, Inc. ... the treatment of bacterial infections, microbial biofilms, and chronic ... its board of directors. , Dr. Sinskey ... at The Massachusetts Institute of Technology, or MIT. He ... 1968. Dr. Sinskey also holds positions as Co-Director of ...
(Date:10/22/2014)... Haelle HealthDay Reporter , TUESDAY, ... adult men may lead to increased blood pressure, according to ... similar rise in blood pressure for young adult women or ... adult women drank lightly or moderately, their risk of high ... "This finding parallels studies in older adult men and women," ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay News) ... for NBC News in Liberia has cleared the virus ... Nebraska Medical Center in Omaha, where he had been treated for ... test confirmed by the U.S. Centers for Disease Control and Prevention ... NBC News reported Tuesday night. "Recovering from Ebola ...
(Date:10/20/2014)... The Advocator Group, LLC is proud ... for Suicide Prevention’s (AFSP) Out of the Darkness walk ... that hosts hundreds of community walks throughout the country ... to help understand and prevent suicide through not only ... , The Advocator Group shares this passion for ...
(Date:10/20/2014)... IN (PRWEB) October 20, 2014 ... Start, a secure cloud solution that enables healthcare ... of the ultimate healthcare-specific customer relationship management (“CRM”) ... meet the unique needs of the healthcare industry, ... experience for providers and patients by combining healthcare ...
Breaking Medicine News(10 mins):Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2
... , , , CARLSBAD, Calif., ... the leader in antisense therapeutics, today announced that management will present ... Conference on Tuesday, August 11, 2009, at 1:00 p.m. ET at ... audio webcast of the presentation will be available on the "Investors ...
... , , SPRING, ... pleased to advise the nutrition and investing community that its flagship ... corporate activities, are easily accessible by simply Googling Cholesterade(R). , ... recent updates on Go Healthy and/or its products, we are confident ...
... , , , , ... high-performance sports water , is targeting ... of major sporting events throughout the late summer and fall. ... cellular hydration in the most demanding environments, from professional sporting events ...
... ... UK have brought every major video conference endpoint manufacturer together for the ultimate in ... altogether under one roof and connect with MCU, Gateway, Firewall, Streaming & Recording infrastructure ... ...
... ... Web site with resources for people with disabilities coincides with Americans with Disabilities Act,s ... ... Americans with Disabilities Act, the U.S. Department of Labor has re-named and re-launched its ...
... , , WASHINGTON, ... announced that they have been chosen as the exclusive ... improvement program, called the IC3 Program(R) (Improving Continuous Cardiac ... Record (EHR) interfacing and data extraction process beginning with ...
Cached Medicine News:Health News:Go Healthy's Marquis Product Cholesterade(R) at Your Fingertips on Google 2Health News:AquaHydrate, First High Performance Sports Water, Targets So Cal Sports Market With Summer Event Support 2Health News:AquaHydrate, First High Performance Sports Water, Targets So Cal Sports Market With Summer Event Support 3Health News:The World of HD Video Conferencing is Now at VideoCentric - One-stop Comparisons of Tandberg, Polycom, Lifesize, Sony, Emblaze-VCON and Aethra 2Health News:The World of HD Video Conferencing is Now at VideoCentric - One-stop Comparisons of Tandberg, Polycom, Lifesize, Sony, Emblaze-VCON and Aethra 3Health News:The World of HD Video Conferencing is Now at VideoCentric - One-stop Comparisons of Tandberg, Polycom, Lifesize, Sony, Emblaze-VCON and Aethra 4Health News:Disability.gov Adds Social Media Tools, Disability Resources and a New Design to Complement Information from 22 Federal Agencies 2Health News:Disability.gov Adds Social Media Tools, Disability Resources and a New Design to Complement Information from 22 Federal Agencies 3Health News:Featherstone Informatics Group, Inc. Named Exclusive Vendor for the American College of Cardiology's Practice-Based Data Registry Program 2
Curved shafts with 2 mm angled platform. Wide serrated handle with dull finish....
Curved shafts with 3.5 mm angled platform and dull finish. Wide serrated handle with dull finish....
15 mm curved blade. 8 mm straight distal tip. Serrated on top of knife. Flat handle....
Grooved roller, on which knife oscillates....
Medicine Products: